Experimental and clinical evidence presented in this book illustrates
that antibodies expressing different specificities can be very effective
in preventing or reversing established transplant rejection. Moreover,
the data leads us to hope that the use of these new therapeutic agents
may allow the induction of specific tolerance to transplant alloantigens
which is the only means to avoid the major risks of sustained
immunosuppression, namely an increased susceptibility to infection and
tumor development. In this volume the editors combine contributions
dealing with very practical aspects of the clinical use of monoclonal
antibodies with a more general discussion on the developments one may
foresee in the near future.